Top

Published in:

01-03-2010 | Research Articles

Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma

Authors: Higinia R. Cárdenes, Tracy R. Price, Susan M. Perkins, Mary Maluccio, P. Kwo, T. E. Breen, Mark A. Henderson, Tracey E. Schefter, Kathy Tudor, Jill Deluca, Peter A. S. Johnstone

Published in: Clinical and Translational Oncology | Issue 3/2010

Title: Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma
Authors: Higinia R. Cárdenes
Tracy R. Price
Susan M. Perkins
Mary Maluccio
P. Kwo
T. E. Breen
Mark A. Henderson
Tracey E. Schefter
Kathy Tudor
Jill Deluca
Peter A. S. Johnstone
Publication date: 01-03-2010
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 3/2010
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-010-0492-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 3/2010

Heat shock proteins as targets in oncology

Colorectal cancer OncoGuia

Primary intracranial malignant peripheral nerve sheath tumour responding to chemotherapy

Clinical practice guidelines in cancer in Catalonia: process and methodology

Why not to publish case reports?

Selection of extreme phenotypes: the role of clinical observation in translational research

Keynote webinar | Spotlight on antibody–drug conjugates in cancer